Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05059379
Other study ID # FDRT-BC017
Secondary ID
Status Recruiting
Phase Phase 3
First received
Last updated
Start date September 20, 2021
Est. completion date August 2027

Study information

Verified date October 2021
Source Fudan University
Contact Zhaozhi Yang, M.D.
Phone 86 18017317126
Email yzzhi2014@163.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Locally advanced breast cancer has high-risk local regional recurrence after surgery. Radiotherapy could reduce the local regional recurrence and improve disease free survival and overall survival. Regional lymph node irradiation is the important part of breast cancer radiotherapy. However, there are some controversies about regional lymph node delineation, especially the supraclavicular irradiation volume. Many studies had confirmed that posterolateral region of the supraclavicular fossa (also named Posterior neck lymph node) had a high risk involvement based on the mapping of recurrence nodes. This randomized phase III trial compares medial supraclavicular lymph node irradiation with entire supraclavicular lymph node irradiation in patients with pathologically positive axillary lymph node and high risk of recurrence after mastectomy or breast conservative surgery. It is not yet known if radiation works better with entire supraclavicular fossa than medial supraclavicular fossa.


Description:

PRIMARY OBJIECTIVE: I. To evaluate whether entire supraclavicular lymph node irradiation is superior to medial supraclavicular lymph node irradiation in terms of disease free survival for patients with positive lymph nodes and high risk of recurrence after breast cancer surgery SECONDARY OBJECTIVES: I. To estimate the difference of overall survival II. to estimate the difference of ipsilateral supraclavicular node recurrence III. to estimate the difference of local regional recurrence IV. to estimate the difference of radiation related toxicities and quality of life. Outline: Beginning 2-12 weeks after the completion of breast cancer surgery and neoadjuvant/adjuvant chemotherapy, patients are randomized to 1 of 2 treatment arms Arm I: Patients undergo breast/chest wall, undissected axillary, internal mammary node and medial supraclavicular node radiation. Conventional fractionated radiotherapy 50Gy/25Fx/5w or hypofractionated 42.5Gy/16Fx/3.5week with IMRT or VAMT technique is recommended. 3DCRT technique is not permitted. Arm II: Patients undergo breast/chest wall, undissected axillary, internal mammary node and entire supraclavicular node radiation. Conventional fractionated radiotherapy 50Gy/25Fx/5w or hypofractionated 42.5Gy/16Fx/3.5week with IMRT or VAMT technique is recommended. 3DCRT technique is not permitted


Recruitment information / eligibility

Status Recruiting
Enrollment 1650
Est. completion date August 2027
Est. primary completion date August 2026
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: 1. ECOG 0-1 2. Newly diagnosed invasive breast cancer 3. Initial clincial diagonosis stage is T1-4, N0-3a/b, M0: If neoadjuvant chemotherapy was not administered: pathological stage is T1-3N2-3a/b, M0; If neoadjuvant chemotherapy was administered:clinical stage III or pathological stage is T1-4N1-3a/bM0. 4. Underwent breast conservative surgery or Mastectomy with or without breast reconstruction with clear negative margin. At least, axillary level I and level II should be cleared with =10 lymph node (including the number of sentinal lymph node) . Level III dissection and internal mamamry node dissection are not required, but may be performed at the discretion of the surgeon. 5. Should receive =6 cycles standard neoadjuvant and/or adjuvant chemotherapy (taxane and/or anthracycline based). 6. Enrolled on the trial within 12 weeks of the later of two dates: the final breast cancer surgical procedure or administration of the last cycle of cytotoxic chemotherapy. 7. For ER and/or PR positive patients, the duration of anticipated endocrine therapy should be=5 year ; For HER2 postive patients, the duration of anticipated herceptin should be 1 year. 8. Writtern, informed consent. Exclusion Criteria: 1. Initinal clinical diagnosis N3c (supraclavicualr node metastasis) 2. T4 or inflamed breast cancer with no good downstage by neoadjuvant chemotherapy 3. Distant metastasis 4. Bilateral breast cancer or previously contralateral breast cancer 5. Positve sentinal lymph node with no axillary dissection 6. ECOG =2 7. Could not tolerate chemotherapy and anti-HER2 target treatment 8. Active infectious 9. History of radiotherapy 10. Serious medical complcation 11. Breast cancer during pregnancy and lactation 12. Had simultaneousl or previous secondary malignancies, except for skin basal cell carcinoma and cervical carcinoma in situ. 13. Inaccessibility for follow-up -

Study Design


Intervention

Radiation:
Entire supraclavicular lymph node radiotherapy
Radiation is delivered to the breast/chest wall, undissected axilla, internal mammary nodes and entire supraclavicular lymph node. Entire supraclavicular lymph node includes medial supraclavicular and posterior neck lymph node.
Medial supraclavicular lymph node radiotherapy
Radiation is delivered to the breast/chest wall, undissected axilla, internal mammary nodes and entire supraclavicular lymph node.

Locations

Country Name City State
China Fudan University Shanghai Cancer Center Shanghai Shanghai

Sponsors (6)

Lead Sponsor Collaborator
Fudan University Affiliated Hospital of Jiangnan University, Guizhou Provincial People's Hospital, Jiangyin People's Hospital, Quanzhou First Hospital, The First Affiliated Hospital of University of Science and Technology of China

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Disease free survival (DFS ) defined as time from randomization until to local, regional, or distant recurrence, or any death, or secondary primary cancer Up to 5 years after completion of radiation therapy
Secondary Overall survival (OS) defined as time from any death Up to 5 years after completion of radiation therapy
Secondary Ipsilateral supraclavicular lymph node recurrence (ISLNR) ) defined as entire ipsilateral supraclavicular lymph node recurrence Up to 5 years after completion of radiation therapy
Secondary Local reigonal recurrence (LRR) chest wall, breast , regional lymph node recurrence Up to 5 years after completion of radiation therapy
Secondary Distance metastasis (DS) any recurrence in all areas beyond local, regional and death due to breast cancer Up to 5 years after completion of radiation therapy
Secondary incidence of adverse events Adverse events categorized using the NCI Common Terminology for Adverse Events Version 4.0 (CTCAE v4.0) Up to 5 years after completion of radiation therapy
Secondary difference of quality of life evaluate the quality of life according to EROTC-QLQ-C30 and QLQ BR23 Up to 5 years after completion of radiation therapy
Secondary differences in upper limb function evaluate the upper limb function by Quick-dash Up to 5 years after completion of radiation therapy
See also
  Status Clinical Trial Phase
Recruiting NCT04681911 - Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer Phase 2
Terminated NCT04066790 - Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer Phase 2
Completed NCT04890327 - Web-based Family History Tool N/A
Completed NCT03591848 - Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility N/A
Recruiting NCT03954197 - Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients N/A
Terminated NCT02202746 - A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer Phase 2
Active, not recruiting NCT01472094 - The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
Recruiting NCT06057636 - Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study N/A
Recruiting NCT06049446 - Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
Recruiting NCT05560334 - A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations Phase 2
Active, not recruiting NCT05501769 - ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer Phase 1
Recruiting NCT04631835 - Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer Phase 1
Completed NCT04307407 - Exercise in Breast Cancer Survivors N/A
Recruiting NCT03544762 - Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation Phase 3
Terminated NCT02482389 - Study of Preoperative Boost Radiotherapy N/A
Enrolling by invitation NCT00068003 - Harvesting Cells for Experimental Cancer Treatments
Completed NCT00226967 - Stress, Diurnal Cortisol, and Breast Cancer Survival
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT06019325 - Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy N/A